Navigation Links
NIH awards $5.5 million grant to Weill Cornell for research into preventing spina bifida
Date:9/26/2011

NEW YORK (Sept. 26, 2011) -- The National Institutes of Health (NIH) has awarded a five-year, $5.5 million Transformative Research Project (T-R01) Award to fund research into risk factors for spina bifida and related congenital defects in which an area of the affected baby's spine or brain is not fully enclosed.

The research will be led by Dr. Margaret Elizabeth Ross and Dr. Christopher E. Mason at Weill Cornell Medical College. Dr. Ross is the director of the Laboratory of Neurogenetics and Development and professor and vice chair for research in the Department of Neurology and Neuroscience, and Dr. Mason is an assistant professor of computational genomics in the Department of Physiology and Biophysics and at the HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine. They will work in collaboration with Dr. Richard H. Finnell of the University of Texas at Austin.

The award to Dr. Ross and Dr. Mason is among 79 awards totaling $143.8 million that were recently announced by the NIH. It is also one of only 17 given in the transformative research category in 2011. According to the NIH: "The Common Fund's NIH Director's Transformative Research Award initiative, formerly known as the Transformative Research Project (TR01), is created specifically to support exceptionally innovative and/or unconventional research projects that have the potential to create or overturn fundamental paradigms."

Spina bifida and other serious neural tube defects (NTDs) develop from a complex interaction between genetic and environmental factors in which the environment influences how the fetus' genetic blueprint is read during development. One critical influence is the addition of methyl groups to DNA that can make it less likely that the modified, methylated gene will be used to make the protein it encodes. The Weill Cornell study seeks to identify which among all the genes in the cell are modified by folic acid levels, and how those patterns can be used to assess individual risk for having a child with spina bifida, or other serious NTDs. They will compare DNA from patients with NTDs with DNA from healthy patients with the ultimate goal of developing more individually targeted and more effective prevention strategies.

The U.S. Public Health Service recommends that all women capable of becoming pregnant should consume folic acid to reduce their risk for having a pregnancy affected by spina bifida and other NTDs. Folic acid is in most multivitamins and many foods, including vegetables like broccoli and spinach, and fruits and juices such as orange juice. Some foods also have folic acid added to them, like certain breakfast cereals and other bread and grain products. Research at Weill Cornell will address questions of how folic acid protects against neural tube defects, how the need for folic acid varies with the genetic makeup of an individual, and whether there are alternative supplements, perhaps working elsewhere in the same pathway as folic acid, that would more effectively promote healthy birth outcomes by providing a patient-specific genetic test before pregnancy begins.

In addition to the Weill Cornell award, three research scientists at Cornell University in Ithaca received a five-year Transformative Research Projects Award (T-R01) of approximately $3.04 million to fight cancer by targeting the regulation of metabolic enzymes. Drs. Richard A. Cerione, professor of pharmacology in the Department of Molecular Medicine, College of Veterinary Medicine, and professor of chemistry and chemical biology in the College of Arts and Sciences; Hening Lin, assistant professor of chemistry and chemical biology; and Robert S. Weiss, associate professor of molecular genetics in the College of Veterinary Medicine, are working on the project, "Succinylation and Malonylation as Novel Protein Modifications in Cancer." The research will focus on a new set of regulatory modifications that occur on proteins and which appear to be important to cancer progression, explain the researchers.

"More specifically, we believe that these modifications help to activate proteins that are responsible for meeting the hefty energy requirements of cancer cells. Thus, if we can block these modifications and the activation of the metabolic proteins, the cancer cells will not be able to meet their energy needs and hopefully die," says Dr. Cerione.


'/>"/>

Contact: John Rodgers
jdr2001@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
Source:Eurekalert

Related biology news :

1. NIH doles out $3M in new innovator awards to 2 UC San Diego faculty
2. NIH awards Clemson bioengineer $1.5 million to improve durability of tissue heart valves
3. Entertainment Software Association Foundation awards grant to FAS for immune attack
4. Audience Selected as Silver Winner in This Years Wall Street Journal Technology Innovation Awards and Winner of the Semiconductors Category
5. NIAID announces 25 new awards to develop radiation countermeasures
6. Human Microbiome Project awards funds for technology development, data analysis and ethical research
7. University success at national engineering awards
8. New Systems Biology Awards enable detailed study of microbes
9. Soil Science Society of America presents awards in Houston
10. ASU researchers receive NIH awards for studies of malaria and emergent disease
11. NIH funds 16 Science Education Partnership Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... February 21, 2017 Der weltweite ... wachsen. Nach einem Gespräch mit mehr als 50 Vertretern aus ... zu überwinden gilt, um diese Prognose zu realisieren. ... ... Mobilisierung der finanziellen Mittel für die Biobank, die Implementierung ...
(Date:2/13/2017)... 13, 2017 Former 9/11 Commission border counsel ... Janice Kephart of Identity Strategy Partners, LLP, ... Trump,s "Executive Order: Protecting the Nation From Foreign ... "As President Trump,s ,Travel Ban, Executive Order ... essentially banned the travel ban, it is important that ...
(Date:2/8/2017)... Feb. 7, 2017  Aware, Inc. (NASDAQ: AWRE ... reported financial results for its quarter and year ended December ... of 2016 was $3.9 million compared to $6.9 million in ... quarter of 2016 was $0.6 million compared to $2.6 million ... fourth quarter of 2016 was $0.5 million, or $0.02 per ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... 23, 2017  SeraCare Life Sciences, Inc., a ... vitro diagnostics manufacturers and clinical laboratories, is ... multiplexed Inherited Cancer reference material ... next-generation sequencing (NGS). The Seraseq™ Inherited Cancer DNA ... from industry experts to validate the ability ...
(Date:3/23/2017)... -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical ... reported financial results for the quarter and year ... update on the company,s clinical development efforts and ... pleased to report that last year was a ... Krammer. "We achieved key clinical milestones and attracted ...
(Date:3/23/2017)... 23, 2017 Kineta, Inc., a biotechnology ... therapies in immuno-oncology, today announced the discovery and ... compounds that activate interferon response factor 3 (IRF3) ... immune-mediated tumor regression in a murine colon carcinoma ... demonstrated complete tumor regression to initial drug treatment ...
(Date:3/23/2017)... According to a report by Transparency Market Research (TMR), ... the presence of a large pool of participants; however, only a ... Sigma-Aldrich, compete with each other in this market. With Proliant being ... of this market in 2016.  ... As of now, a large number of vendors are ...
Breaking Biology Technology: